Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.61 |
| ▸ | HTR2A | P28223 | 9/20 | 0.61 |
| ▸ | HTR1A | P08908 | 8/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433199 | 0.88 | DRD2 (0.75) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL28719638 | 0.86 | DRD2 (0.65) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL12859637 | 0.84 | DRD2 (0.56) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL24719761 | 0.84 | DRD2 (0.66) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL293264 | 0.83 | DRD2 (0.65) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL293666 | 0.83 | DRD2 (0.65) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL22302867 | 0.83 | DRD2 (0.63) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL4573898 | 0.82 | DRD2 (0.67) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL30176777 | 0.82 | DRD2 (0.67) | DRD2HTR2AHTR1AHTR2CADRA1A | |
| SCHEMBL31733938 | 0.82 | DRD2 (0.67) | DRD2HTR2AHTR1AHTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | DRD2 139/4885HTR2A 92/4885HTR1A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.